Skip to content
2000
Volume 21, Issue 10
  • ISSN: 1570-1808
  • E-ISSN: 1875-628X

Abstract

Background: The increasing prevalence of depression has become a global health issue. Currently approved anti-depressive including 5-hydroxytryptamine (5-HT), dopamine (DA), norepinephrine (NE), triple reuptake inhibitors (TRIs) and glutamate -methyl--aspartate (NMDA) receptor antagonists have limited effects because of their insufficient efficacy and/or slow onset of action. Developing multifunctional antidepressants that can modulate 5-HT, DA, NE, and NMDA simultaneously can potentially overcome the current drug defects. Objective: This study aimed to explore leads for the development of multi-functional anti-depressive agents that simultaneous triple reuptake inhibitory and NMDA-GluN2B receptor antagonistic activities. Methods: Potential leads were screened virtually from the TCMSP database based on the 3DPharmacophore model of TRIs followed by the molecular docking into NMDA-GluN2B receptor, BBB score, and the toxicity evaluation. The biological activities of discovered leads on 5-HT, NE, and DA reuptake and their effect on the NMDA-GluN2B receptor were evaluated via radio-labeled neurotransmitters and competition radio-ligand binding experiment with [3H] ifenprodil, respectively. Lastly, the antidepressant effect of these potential leads was determined through the forced swim test in mice. Results: Two compounds were attained as potential leads after the aforementioned experiments. Further biological evaluation identified Hit-2 as a promising lead that exerted favorable triple 5- HT/DA/NE reuptake inhibitory activity (66.98% inhibition rate at 10 μM against NET, 73.01% inhibition rate at 1 μM against DAT and 86.27% inhibition rate at 1 μM against SERT), as well as potent NMDA-GluN2B receptor antagonistic activity (=115.73 ± 3.54 nM). The antidepressant activity of Hit- 2 was confirmed through experiments Conclusion: Hit-2 not only simultaneously inhibited the reuptake of 5-HT, DA, and NE, and acted as an NMDA-GluN2B receptor antagonist but also showed antidepressant activity. These findings may serve as a structural basis for the further development of multi-functional anti-depressive agents.

Loading

Article metrics loading...

/content/journals/lddd/10.2174/1570180820666230418104418
2024-08-01
2024-12-25
Loading full text...

Full text loading...

/content/journals/lddd/10.2174/1570180820666230418104418
Loading

  • Article Type:
    Research Article
Keyword(s): 5-hydroxytryptamine; dopamine; NMDA-GluN2B; TCMSP; triple reuptake inhibitors; TRIs
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test